Posted by Michael Wonder on 03 Jun 2020
Lower prices and greater patient access — lessons from Germany’s drug purchasing structure
3 June 2020 - The German system for determining drug prices features collective negotiations on the part of competing health plans.
It also creates incentives for agreement, limits price increases not justified by new evidence, and avoids heavy burdens on physicians and patients.
